ProteoTech, Inc.
12040 115th Ave., NE
Kirkland, WA 98034
Office: (425) 823-0400
Fax: (425) 823-8508
E-mail: info@proteotech.com
A World Leader in Therapeutics and
Diagnostics Targeting Amyloid Diseases
 | ||||
|
SMALL MOLECULE APPROACH TO TREATING ALZHEIMER'S DISEASE
ProteoTech is one of a few companies at the forefront of developing disease-modifying small molecule compounds targeted at inhibiting the formation and aggregation of a toxic substance found in patients with Alzheimer's disease known as beta-amyloid protein deposits.
Beta-amyloid protein deposits and amyloid plaques occur normally within all aging brains. But, unlike the normal aging brain, Alzheimer's disease brains form and accumulate amyloid deposits and plaques at a much greater rate and densities, thereby leading to a cascade effect that over time, results in the death of healthy brain cells and patient memory loss.
ProteoTech's innovative small molecule, Exebryl-1®, is currently being tested for safety in FDA authorized Human Phase I Clinical Trials. Exebryl-1® has shown in laboratory research to interfere with the formation of toxic beta-amyloid deposits and fibrils which are believed by medical professionals and researchers to be a key component in the progression of Alzheimer's disease.
Initial studies suggest that Exebryl-1® may also have an important dual capacity by inhibiting and reducing tau protein from forming paired helical filaments, important in neurofibrillary tangle formation. The presence of neurofibrillary tangles in brain containing tau protein is an important pathological hallmark of Alzheimer's disease. Further studies are ongoing to confirm these exciting findings.
Exebryl-1® may be the first orally bioavailable small molecule drug that affects both amyloid plaque and neurofibrillary tangle accumulation, the two major characteristic and pathological lesions of Alzheimer's disease.
|
||||
 |
